<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366828">
  <stage>Registered</stage>
  <submitdate>5/08/2014</submitdate>
  <approvaldate>15/09/2014</approvaldate>
  <actrnumber>ACTRN12614000992606</actrnumber>
  <trial_identification>
    <studytitle>The healing of pressure ulcers treated with electrical stimulation delivered by the cathode versus the alternating use of the cathode and anode. </studytitle>
    <scientifictitle>The healing of pressure ulcers in geriatric patients treated with high voltage pulsed current delivered by the cathode versus the alternating use of the cathode and anode. A prospective, randomized, controlled, clinical study    </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Wound healing

</healthcondition>
    <healthcondition>Pressure ulcers</healthcondition>
    <healthcondition>Chronic wound healing 
</healthcondition>
    <healthcondition>Pressure ulcer healing</healthcondition>
    <conditioncode>
      <conditioncode1>Physical Medicine / Rehabilitation</conditioncode1>
      <conditioncode2>Physiotherapy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Physical Medicine / Rehabilitation</conditioncode1>
      <conditioncode2>Other physical medicine / rehabilitation</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Aim of study

The purpose of this prospective, parallel-group, randomized, controlled, clinical trial is to compare the healing progress of pressure ulcers (PU) in geriatric people after 6 weeks of intervention involving standard wound care (SWC), SWC in conjunction with high voltage pulsed current (HVPC) delivered by the cathode, and SWC combined with HVPC delivered by the cathode and the anode as the treatment electrodes.   

Demographic information on the subjects will be compiled during standardized interviews and physical examinations, as well as from additional examinations of the subjects and the documentation of their concomitant diseases. 

The patients physical and mental conditions, activity, mobility and incontinence will be assessed using the Norton scale (a score &lt; 14 indicated a high risk of PU development). To assess the possibility of friction and shear and wound moisture, as well as sensory perception of the patients, their physical activity and mobility the Braden Scale will be applied (a score &lt; 16 pointed to a high risk of PU development). Patients nutritional status will be identified by means of the Nutritional Risk Score (NRS-2002). 

Wound severity at enrolment will be assessed based on the National and European Pressure Ulcer Advisory Panel criteria: Stage II ulcers = partial-thickness loss of the dermis presenting as a shallow open ulcer with a red pink wound bed, without slough; Stage III ulcers = full-thickness tissue loss; subcutaneous fat may be visible but bone, tendon or muscle are not exposed; Stage IV ulcers = full-thickness tissue loss with eposed tendom, muscle or bone. Slough or eschar may be present on some parts of the wound bed. Can include unermining and tunneling.


SWC programme administered to all groups. 

All patients will be treated to prevent the development of new pressure ulcers. Pressure-redistribution surfaces, devices and pillows will be applied as needed. A nurse will reposition the immobile patients every 2 hours at the least. 

Blood tests will be carried out to screen for nutritional status markers and metabolic disorders such as anaemia (iron deficiency anaemia or anaemia of chronic disease), thyroid dysfunction, impaired glycaemic control, dehydration, protein deficit, hypoalbuminemia. 

Wounds will be regularly assessed by the attending physician over the period of the study to select topical treatments appropriately addressing moisture control, bacterial burden, and debridement needs; microbiological culture and sensitivity tests will also be performed. 

A team formed of a physician, a nurse, a physical therapist and a dietician will make comprehensive, interdisciplinary assessments of the patients to develop SWC programmes meeting their specific demands, for instance consisting of nutritional intervention, optimization of the wound dressing protocol, and incontinence management. The clinician caregivers will be blinded to participants group. 

Patients in all groups will receive similar standard topical care, selected to address their individual needs and to promote moist interactive healing. 

All immobilized patients will receive low-molecular-weight heparin (enoxaparin) as a standard therapy. Patients with elevated leukocyte levels will be treated with antibiotics selected following microbiological culture and sensitivity testing of the PU swab.



Electrical stimulation with the cathode 

In the cathode HVPC group, patients will be administered HVPC in addition to SWC. 

The device for applying HVPC will be the Intelect Advanced Combo (by Chattanooga, USA). The device generates a twin-peak monophasic pulse consisting of two 77- microseconds exponential pulses in rapid succession (the twin-peak pulse duration was 154 microseconds). Pulse frequency will be 100 pps. Current intensity will be set within 0.25-0.30 A, so patients will only experience sensory effects (without motor reactions). Voltage will be set to 100 V and the electrodes will deliver an electrical charge of 250 microcoulomb per second. This HVPC protocol has been selected because of the positive results of earlier clinical trials on patients with pressure ulcers (Pus) and venous leg ulcers (VLUs).

Each patient will have their own set of electrodes made of conductive carbon rubber. The treatment electrode (of a size matching the wound surface area) will be placed on an aseptic gauze pad saturated with physiological saline overlaying the wound site. The dispersive electrode (bigger than the treatment electrode) closing the electrical circuit will be positioned about 20 cm from the PU (proximally or distally, depending on where the PU developed). 

Over the period of the intervention, the negative electrode (cathode) will be used to treat pressure ulcers. The authors of some other clinical studies on PUs have also used cathodal stimulations. 

In the experiment, five 50-minute sessions will be held per week (one a day), following the approach adopted by other authors.  

Pressure ulcers receiving SWC and cathode HVPC will be monitored for healing progress for 6 weeks or until wounds close, whichever occurs first. 




Electrical stimulation with the cathode and the anode

Patients in the cathode/anode HVPC group will receive HVPC in the same way as patients in the cathode HVPC group, but first the cathode will be applied as the treatment electrode to stimulate the growth of granulation tissue. Cathodal stimulation will be used in week 1 (5 days) and then it will be replaced by anodal stimulation for the remainder of the experiment. The authors of other clinical studies on VLUs and PUs used the same sequence of cathodal and anodal stimulation.

Before and after each ES procedure, the electrodes will be sterilized in a disinfectant solution. Pressure ulcers will be thoroughly cleansed with a 0.9% sodium chloride solution and covered with the earlier described dressings immediately after the procedure.

Pressure ulcers receiving SWC and cathode/anode HVPC will be monitored for healing progress for 6 weeks or until wounds close, whichever occurs first. 

</interventions>
    <comparator>Control group
Patients in the control group will be treated to prevent the development of new pressure ulcers. Pressure-redistribution surfaces, devices and pillows will be applied as needed. A nurse will reposition the immobile patients every 2 hours at the least. 

Blood tests will be carried out to screen for nutritional status markers and metabolic disorders such as anaemia (iron deficiency anaemia or anaemia of chronic disease), thyroid dysfunction, impaired glycaemic control, dehydration, protein deficit, hypoalbuminemia. 

Wounds will be regularly assessed by the attending physician over the period of the study to select topical treatments appropriately addressing moisture control, bacterial burden, and debridement needs; microbiological culture and sensitivity tests will also be performed. 

A team formed of a physician, a nurse, a physical therapist and a dietician will make comprehensive, interdisciplinary assessments of the patients to develop SWC programmes meeting their specific demands, for instance consisting of nutritional intervention, optimization of the wound dressing protocol, and incontinence management. The clinician caregivers will be blinded to participants group. 

Patients will receive similar standard topical care, selected to address their individual needs and to promote moist interactive healing. All immobilized patients will receive low-molecular-weight heparin (enoxaparin) as a standard therapy. Patients with elevated leukocyte levels will be treated with antibiotics selected following microbiological culture and sensitivity testing of the PU swab.


In addition to standard wound care described above, the control group will also receive sham ES. The electrodes will be arranged in the same way as in the ES groups and all current parameters will also be displayed on the monitor, but the current itself will not be applied.  Five 50-minute sessions of sham ES will be held per week (one a day).


Pressure ulcers receiving SWC in the control group will be monitored for healing progress for 6 weeks or until wounds close, whichever occurs first. 
</comparator>
    <control>Active</control>
    <interventioncode>Rehabilitation</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absolute average change in WSA (cm2) after treatment in relation to its baseline in all groups (showing how effective treatment will be in particular groups)

WSA will be determined using the same method that was already employed in several previous clinical trials. First wound contours will be copied onto transparent film sheets. The contours will be then measured with the planimeter to establish the surface area of each wound. The obtained data will be processed by a digitizer (Mutoh Kurta XGT, Altek, USA) connected to a personal computer (C-GEO v. 4.0 Nadowski, PL) which will be also used to store the results. Measurement errors caused by different shapes of the wounds may range from 2.7%  (for pressure ulcers of 60 to 70 cm2 in size) to 37.9% (for pressure ulcers &lt; 1 cm2). The method with which measurement errors will be calculated can be found in our earlier study.
</outcome>
      <timepoint>At baseline, and week6</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The percentage change/decrease in WSA after 6 weeks of intervention with SWC + sham ES, SWC + cathode HVPC, and SWC + cathode/anode HVPC (to compare changes in PU surface area between the groups).

The formula for calculating percentage WSA reduction from baseline (%WSA) will be the following:
%WSA = initial WSA (cm2)  WSA (cm2) at week 6 x 100% /  Initial WSA (cm2)
                                     </outcome>
      <timepoint>At baseline, and week 6</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The Gilman's parameter calculated to ensure the comparability of healing progress regardless of wound shape 

The Gilman's parameter (GP) will be calculated as:
                       
GP= S / p
S = (Si - Sf)
Si, Sf - initial and final wound surface areas
p = (pi + pf) / 2
pi, pf - initial and final wound perimeter
</outcome>
      <timepoint>At baseline, and week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Wound healing rates presenting average weekly relative change in wound area (%/week) calculated to compare the groups. 

The weekly relative change in ulcer area (%/week) will be calculated as:                             
%/week = Percentage change in WSA (%WSA) / Total number of weeks of treatment
</outcome>
      <timepoint>At baseline, and week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage change in WSA will be assessed after each week of treatment to find out in which week the change was the greatest. 

The following formulas will be used to this end:
                        
%WSAweek1= initial WSA (cm2)  WSA (cm2) at week1 x100% / Initial WSA (cm2)
                                        
%WSAweek2= WSA(cm2) at week1  WSA(cm2) at week2 x100% / WSA(cm2) at week1
                        
%WSAweek3= WSA(cm2) at week2  WSA (cm2) at week3 x100% / WSA(cm2) at week2

%WSA/week4= WSA(cm2) at week3  WSA (cm2) at week4
 x100% / WSA(cm2) at week3

%WSA/week5= WSA(cm2) at week4  WSA (cm2) at week5
 x100% / WSA(cm2) at week4

%WSA/week6= WSA(cm2) at week5  WSA (cm2) at week6
 x100% / WSA(cm2) at week5

</outcome>
      <timepoint>At baseline, week1, week2, week3, week4, week5, and week6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of PUs the WSA of which will be significantly smaller at the end of week 6 of intervention (by at least 50%), that will heal completely or will increase (WSA greater than the baseline).</outcome>
      <timepoint>At baseline, and week6</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patient eligibility for the experiment will be established by their physician according to the following criteria: older than 60 years of age, at high risk of PU development (a score on the Norton scale below 14 points), with a stage II, III or IV pressure ulcer of at least 0.5 cm2 in size and of minimal duration 4 weeks.</inclusivecriteria>
    <inclusiveminage>60</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Any condition that might prevent the application of electrical stimulation (ES) (a cardiac pacemaker, cancer, osteomyelitis, PU in need of surgical intervention). </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patient eligibility for the experiment will be established by their physician. The selected patients (or their legal guardians) who will give their consent to participate in the study will be randomly assigned to the control group (SWC plus sham ES), the cathode HVPC group (SWC plus cathode HVPC) or the cathode/anode HVPC group (SWC plus cathode/anode HVPC) using a concealed process.

Patient distribution among groups will be independent of when and who will deliver the treatment. An independent person will receive three batches of 25 pieces of paper, each marked with a letter indicating to which group the patient should go, i.e. A for the SWC+cathodal HVPC group, B for the SWC+cathodal/anodal HVPC group and C  for the SWC+sham ES group. The person, unaware of what the symbols mean, will  insert the pieces of paper into 75 envelopes randomly drawn by the computer. The sealed envelopes will be transferred to the main investigator in charge of patientsâ€™ allocation to groups.  

Before the treatment, the envelopes will be opened one-by-one in the presence of a physiotherapist and the patient concerned will be directed to the appropriate study group.</concealment>
    <sequence>Simple randomisation using numbered envelopes</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>To determine group sizes for the experiment, a pilot study was carried out. Because the results obtained with the random pilot sample had unimodal distribution and skewness and flatness were smaller than 2.5, the arithmetic average and standard deviation were chosen for the experiment as good measures of central value and dispersion.

Based on type I error, probability a = 0.05 and test power 1-beta = 0.90 were accepted for the experiment. An assumption was made that to assess wound healing progress in each group, the minimum statistically significant difference would be set at 25% of the baseline. According to the assumptions, a group in the experiment should have at least 20 patients (60 patients in three groups), but the actual size of the sample will be increased to 75 randomly selected patients to allow for possible dropouts. Statistical calculations were performed using the Statistica 10 package

After the experiment, patients characteristics will be tested for normality of distribution using the Shapiro-Wilk W test. 
In the case of normal distributions, the parametric ANOVA test will be used, and in the case of non-normal distributions, the non-parametric tests (Kruskal-Wallis analysis of variance for inter-group comparisons and Friedmans ANOVA for intragroup comparisons) will be used to establish statistical significance.  

Patients characteristics will also be tested for skewness, kurtosis and modality of distributions. In the cases when skewness and kurtosis are smaller than 4 and the distributions are unimodal, arithmetic averages and standard deviations will be used as the measures of central value and dispersion.

The level of statistical significance in all tests will be p &lt; 0.05.  

The statistical analysis will be performed using the Statistica software by StatSoft (licenced to the Medical University of Silesia).

All patients in the experiment will be assessed for the homogeneity of distribution of their characteristics. 
The mean wound surface area (WSA) before and after treatment will be compared within particular groups. The mean percentage change in wound area, the value of the Gilmans parameter and mean weekly change in WSA will be calculated (at week 6) in all groups and then an inter-group comparison will be performed. At the end of intervention (week 6), the healing rates of PUs that have significantly improved (decreasing by at least 50%), closed or worsened (i.e. having WSA greater than baseline) will be calculated and compared between the groups.
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>21/09/2014</anticipatedstartdate>
    <actualstartdate>22/09/2014</actualstartdate>
    <anticipatedenddate>27/02/2015</anticipatedenddate>
    <actualenddate>27/04/2015</actualenddate>
    <samplesize>71</samplesize>
    <actualsamplesize>63</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Silesia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Academy of Physical Education, </primarysponsorname>
    <primarysponsoraddress>Academy of Physical Education, 
Department of Physical Therapy, 
Mikolowska 72A street
40-065 Katowice</primarysponsoraddress>
    <primarysponsorcountry>Poland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Academy of Physical Education</fundingname>
      <fundingaddress>Academy of Physical Education, 
Department of Physical Therapy, 
Mikolowska 72A street
40-065 Katowice
</fundingaddress>
      <fundingcountry>Poland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Clinical practice guidelines in Europe, the United States, and Canada recommend applying electrical stimulation (ES) to chronic pressure ulcers resistant to  standard wound care (SWC). However, the exact rules for applying ES to different-stage wounds are still to be developed and tested in clinical studies. It is though that the polarity of the treatment electrode used during ES procedures is significance for the healing process. 

Despite the specific rules for treating human wounds with the anode and the cathode not having been developed yet, the results of in vitro and in vivo studies indicate that both these electrodes can promote wound healing and that the polarity of the treatment electrode should match the wound healing stage.

Clinical studies differ in which electrode is used as the treatment electrode. Some authors stimulate wounds with the anode and reverse polarity to negative only if healing progress is not satisfactory. In other studies, the cathode is applied for the length of treatment or for the first 1-3 weeks after which polarity is reversed every week or the anode is introduced for the remainder of treatment. 

According to the authors of in vitro studies, cells involved in tissue repair migrate toward the electric field created by the anode or the cathode. In cell cultures, the anode enhances the motility of macrophages and neutrophils, but human keratinocytes, fibroblasts and bovine corneal epithelial cells migrate directionally toward the cathode. The results of in vitro studies suggest that anodal stimulation is appropriate for increasing macrophage and phagocyte activity during the wounds inflammatory phase, whereas cathodal stimulation can be effective in the proliferative phase of the wound healing process.  

However, the results of in vivo experiments with animals are not consistent. A series of studies in vivo studies with rabbits carried out in the years 1987-1995 suggests that in the initial phases of treatment negative-polarity ES should be administered (mainly to stimulate the granulation tissue formation) and positive-polarity ES afterwards to encourage wound re-epithelization. On the other hand, studies conducted in the 1990s and in the first decade of the 2000s showed anodal stimulation to have a positive effect in the inflammatory phase of new wounds and the cathode to be effective in stimulating granulation tissue formation and re-epithelization processes.     

More experiments are necessary to develop clear rules on how wounds should be treated with the cathode and anode.

Our experiment aims to expand the knowledge of how HVPC delivered by, respectively, the cathode and the anode as the treatment electrodes contributes to the healing of stage II - IV pressure ulcers in geriatric people at high risk of PU development. In the experiment, cathodal and anodal HVPC will be applied to treat pressure ulcers and will be compared for effectiveness.       

Our study is specifically designed to test the following hypotheses:

1. Both cathodal and cathodal/anodal HVPC administrated as part of an interdisciplinary wound care program improve the healing of stage II - IV pressure ulcers

2. Pressure ulcers stimulated by cathodal HVPC for six weeks heal faster than PUs receiving only SWC and PUs receiving cathodal stimulation in the first week of treatment and anodal stimulation for the remaining 5 weeks .

Another purpose of the experiment is gain new knowledge about the efficacy of HVPC. 
</summary>
    <trialwebsite />
    <publication>The Efficacy of Pressure Ulcer Treatment With Cathodal and Cathodal-Anodal High-Voltage Monophasic Pulsed Current: A Prospective, Randomized, Controlled Clinical Trial.

Anna Polak, Luther C Kloth, Edward Blaszczak, Jakub Taradaj, Agnieszka Nawrat-Szoltysik, Tomasz Ickowicz, Ewa Hordynska, Andrzej Franek, Cezary Kucio.

Phys Ther 2017;97:777-789. </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Research Ethics Commitee from the Academy of Physical Education in Katowice, Poland</ethicname>
      <ethicaddress>Mikolowska 72A street
40-065 Katowice
</ethicaddress>
      <ethicapprovaldate>15/05/2014</ethicapprovaldate>
      <hrec>4/2014</hrec>
      <ethicsubmitdate>2/04/2014</ethicsubmitdate>
      <ethiccountry>Poland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Anna Polak</name>
      <address>Department of Physical Therapy, 
Academy of Physical Education, 
Mikolowska 72A street, 
40-065 Katowice</address>
      <phone>+48322075129</phone>
      <fax />
      <email>a.polak@awf.katowice.pl; polanna@op.pl</email>
      <country>Poland</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Anna Polak</name>
      <address>Department of Physical Therapy, 
Academy of Physical Education, 
Mikolowska 72A street, 
40-065 Katowice</address>
      <phone>+48322075129</phone>
      <fax />
      <email>a.polak@awf.katowice.pl; polanna@op.pl</email>
      <country>Poland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Anna Polak</name>
      <address>Department of Physical Therapy, 
Academy of Physical Education, 
Mikolowska 72A street, 
40-065 Katowice</address>
      <phone>+48322075129</phone>
      <fax />
      <email>a.polak@awf.katowice.pl; polanna@op.pl</email>
      <country>Poland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anna Polak</name>
      <address>Department of Physical Therapy, 
Academy of Physical Education, 
Mikolowska 72A street, 
40-065 Katowice</address>
      <phone>+48322075129</phone>
      <fax />
      <email>a.polak@awf.katowice.pl; polanna@op.pl</email>
      <country>Poland</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>